CD43/Sialophorin Antibody (DF-T1), Janelia Fluor™ 646, Novus Biologicals™

CD43/Sialophorin

Monoclonal

Janelia Fluor 646

50mM Sodium Borate with 0.05% Sodium Azide

SPN

Myeloblastic KG1 cells were used as the immunogen for this antibody.

0.1 mL

Primary

It recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation), identified as CD43 [Workshop IV]. Epitope of monoclonal antibody Bra7G is clearly different from that of monoclonal antibody DF-T1, called b as opposed to a for DF-T1. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.

Store at 4°C in the dark.

Western Blot, Flow Cytometry, ELISA, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin)

DF-T1

Western Blot, Flow Cytometry, ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin

CD43 antigen, CD43), Galactoglycoprotein, GALGP, Leukocyte sialoglycoprotein, Sialophorin, sialophorin (gpL115, leukosialin, CD43)

Mouse

Protein A or G purified

B Cell Development and Differentiation Markers, Immunology

6693.0

Human

IgG1 κ